Clinical Genomics Expands Strategic Relationship with Quest Diagnostics and Further Increases Momentum for Innovative First-Line Colorectal Cancer Screening Blood Test
Quest Diagnostics Incorporated (DGX)
Last quest diagnostics incorporated earnings: 4/22 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
ir.questdiagnostics.com
Company Research
Source: GlobeNewswire
-- Advances key development milestones for the Trident Program -- -- Further strengthens strategic alliance with Quest Diagnostics focused on the Trident Program for CRC screening -- BRIDGEWATER, N.J., April 30, 2020 (GLOBE NEWSWIRE) -- Clinical Genomics (“CG” or the “Company”), a provider of advanced cancer diagnostic solutions, including liquid biopsy tests, today announced key business updates related to Trident, the Company’s first-line Colorectal Cancer (“CRC”) screening blood test program, and its strategic alliance with Quest Diagnostics (NYSE: DGX) (“Quest”), the world's leading provider of diagnostic information services. Trident Program for CRC Screening Potential to develop a first-line CRC screening blood test.With data from 1,621 subjects, presented at United European Gastroenterology Week(1), the Trident Program has one of the largest validation data sets of any potential first-line blood test. These data demonstrate performance well within the range of sensitivity
Show less
Read more
Impact Snapshot
Event Time:
DGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DGX alerts
High impacting Quest Diagnostics Incorporated news events
Weekly update
A roundup of the hottest topics
DGX
News
- Octave Bioscience Forms Strategic Collaboration with Quest Diagnostics to Expand Patient Access to the Octave® Multiple Sclerosis Disease Activity (MSDA) Test Across the United States [Yahoo! Finance]Yahoo! Finance
- Octave Bioscience Forms Strategic Collaboration with Quest Diagnostics to Expand Patient Access to the Octave® Multiple Sclerosis Disease Activity (MSDA) Test Across the United StatesBusiness Wire
- Function Health's $2.5 Billion Bet And Are Blood Testing Startups Sustainable [Forbes]Forbes
- Quest Diagnostics (DGX): A Fresh Look at Valuation After Strong Q3 Earnings and Raised Outlook [Yahoo! Finance]Yahoo! Finance
- How the Narrative Around Quest Diagnostics Is Evolving After Recent Results and Analyst Updates [Yahoo! Finance]Yahoo! Finance
DGX
Earnings
- 10/21/25 - Beat
DGX
Sec Filings
- 11/28/25 - Form 4
- 11/28/25 - Form 4
- 11/25/25 - Form 144
- DGX's page on the SEC website